PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | C0022658|renal disease |
| Sentences | 41 |
| PubMedID- 20075931 | Increased aortic stiffness is an independent predictor of death from cardiovascular disease in patients with end-stage renal disease (esrd). |
| PubMedID- 25556309 | Protein-energy wasting plays an important role in the increased risk of mortality from cardiovascular disease in people with end-stage renal disease. |
| PubMedID- 25050994 | Correlations of mthfr 677c>t polymorphism with cardiovascular disease in patients with end-stage renal disease: a meta-analysis. |
| PubMedID- 24416142 | Demographic and clinical data including age, gender, body mass index (bmi), socioeconomic status (income and education level, living condition, etc), primary renal disease, the presence of cardiovascular disease (cvd) and diabetes mellitus (dm) were collected at baseline. |
| PubMedID- 26374600 | Background: secondary hyperparathyroidism is a common condition in patients with end-stage renal disease and is associated with osteoporosis and cardiovascular disease. |
| PubMedID- 22045239 | The potential of proteomics for the identification and study of new biomarkers in the pathophysiology of cardiovascular disease in patients with end-stage renal disease is also discussed. |
| PubMedID- 22020086 | Increased vascular calcification, possibly due to the biochemical problem of calcium (ca) and phosphate excess, has been associated with cardiovascular disease in patients with end stage renal disease. |
| PubMedID- 23483304 | Increased risk of cardiovascular disease in patients with renal disease is the reason for their enhanced morbidity and mortality. |
| PubMedID- 23296279 | Several studies have reported a high prevalence of cardiovascular disease in patients with end-stage renal disease (esrd). |
| PubMedID- 24260402 | Data regarding age, gender, primary renal disease, history of cardiovascular disease (cvd), and the presence of dm were collected at the baseline. |
| PubMedID- 24662786 | This review sets out the clinical and diagnostic aspects of aopps in these diseases such as: renal diseases with different etiology, cardiovascular diseases, as well as connected with metabolic disturbances - e.g. |
| PubMedID- 24797080 | Demographic and clinical data including age, gender, body mass index (bmi), primary renal disease, history of cardiovascular disease (cvd), and presence of diabetes mellitus (dm) were collected at baseline. |
| PubMedID- 23226378 | Demographic and clinical data including age, gender, body mass index (bmi), primary renal disease, history of cardiovascular disease (cvd), and presence of diabetes mellitus (dm) were collected at baseline. |
| PubMedID- 25945353 | Presence of left ventricular hypertrophy and arterial stiffness are independent determinants of cardiovascular disease in patients with end-stage renal disease [10]. |
| PubMedID- 22476965 | Impact of dialysis modality on the survival of end-stage renal disease patients with or without cardiovascular disease. |
| PubMedID- 23380985 | Background/aims: atherosclerosis and inflammation are the most important risk factors in the pathogenesis of cardiovascular diseases (cvd) in patients with end-stage renal disease (esrd). |
| PubMedID- 20308998 | Available pharmacological therapies have been largely ineffective in ameliorating oxidative stress, inflammation, hdl deficiency and/or dysfunction, and the associated atherosclerosis and cardiovascular disease in patients with end-stage renal disease. |
| PubMedID- 22371797 | In an era when cardiovascular mortality in developed countries has been declining in the general population, no such reduction in mortality from cardiovascular diseases in patients with end-stage renal disease has been noted. |
| PubMedID- 24586350 | Therefore, apo e knockout mice are an accepted model for studying atherosclerosis in ckd., of note, atherosclerotic lesions in these mice are very similar to those in human beings [25], although the presentation of cardiovascular disease in patients with renal disease is often atypical [26]. |
| PubMedID- 22382216 | Cardiovascular disease in patients with end-stage renal disease on hemodialysis in a developing country. |
| PubMedID- 25431275 | Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ontarget and transcend studies. |
| PubMedID- 23533064 | Progression to end-stage renal disease and development of cardiovascular disease are two major poor outcomes of ckd 35. we also analyzed the association between the study groups and cardiovascular events, and found the group with higher indexed lad and lower albumin was associated with an increase in cardiovascular events, which suggested la enlargement and hypoalbuminemia might also have a synergic effect on the risk of adverse cardiovascular outcomes. |
| PubMedID- 22200429 | Ages and cardiovascular diseases in patients with end-stage renal diseases. |
| PubMedID- 22529163 | However, it is unknown whether any of these approaches can reduce the high risks of death and cardiovascular disease in patients with end-stage renal disease. |
| PubMedID- 26231610 | Few older people with even advanced ckd will progress to end-stage renal disease; the risk of death from cardiovascular disease or infection often supervenes long before the need for renal replacement therapy. |
| PubMedID- 24561478 | Atherosclerosis is an inflammatory vascular disease frequently associated with renal disease [19]. |
| PubMedID- 24314936 | The prevalence and types of cardiovascular disease in patients with end-stage renal disease undergoing renal transplantation. |
| PubMedID- 22609477 | The intercellular adhesion molecule-1 (icam-1) gene polymorphism k469e in end-stage renal disease patients with cardiovascular disease. |
| PubMedID- 23462068 | Introduction: early detection of cardiovascular disease in children with end-stage renal disease is essential in order to prevent cardiovascular morbidity and mortality in early adulthood. |
| PubMedID- 26298738 | Objective: in end-stage renal disease, deleterious effect of sarcopenia on cardiovascular disease has been explained mainly by chronic inflammation. |
| PubMedID- 20460938 | Despite medical progress, high morbidity and mortality rates, due primarily to cardiovascular diseases, have persisted in patients with end-stage renal disease (esrd). |
| PubMedID- 26000261 | Background: hyperhomocysteinemia is a risk factor for cardiovascular disease particularly in patients with end stage renal disease (esrd). |
| PubMedID- 24049104 | When analysing the association between bmi as a categorical variable with lvm, patients who were overweight or obese had a significantly higher lvm compared with those with normal weight, both in the unadjusted and adjusted analyses (table 2).table 2.the association between both bmi and wc with lvm using linear regression analysis in cross-sectional data left ventricular mass (g) (n = 179)left ventricular mass height2.71 indexed (g/m2.71) (n = 179)left ventricular mass, body surface area indexed (g/m2) (n = 179)model 1: unadjmodel 2: adjamodel 3: adjbmodel 1: unadjmodel 2: adjamodel 3: adjbmodel 1: unadjmodel 2: adjamodel 3: adjbbmi (kg/m2) continuous2.1 (−0.70; 4.8)4.7 (2.0; 7.4)5.5 (2.9; 8.1)1.3 (0.59; 2.0)1.4 (0.65; 2.1)1.6 (0.90; 2.3)−0.048 (−1.9; 0.92)0.27 (−1.1; 1.7)0.74 (−0.62; 2.1)bmi categorical normal weight: 18.5–24.9 kg/m2111111111 overweight: 25–29.9 kg/m236.4 (0.11; 72.7)37.3 (5.1; 69.6)50.6 (19.5; 81.7)9.0 (−0.12; 18.1)6.7 (−1.8; 15.3)10.1 (1.8; 18.4)7.3 (−11.4; 26.0)5.7 (−11.3; 22.7)13.4 (−3.0; 29.9) obesity: ≥30 kg/m239.0 (3.11; 74.9)58.9 (24.6; 93.2)71.2 (38.2; 104.2)16.0 (7.0; 25.0)14.5 (5.4; 23.6)17.6 (8.8; 26.4)0.29 (−18.2; 18.7)4.7 (−13.3; 22.8)11.9 (−5.4; 29.3)waist circumference (cm)1.2 (0.15; 2.3)1.2 (0.14; 2.3)1.7 (0.61; 2.7)0.46 (0.19; 0.74)0.28 (0.00; 0.57)0.39 (0.10; 0.67)0.02 (−0.54; 0.58)−0.18 (−0.74; 0.39)0.06 (−0.49; 0.61)amodel 2: adjusted for age, sex, smoking, primary renal disease and history of cardiovascular disease.bmodel 3: adjusted for confounders of model 2 + egfr.figure 2:correlation between bmi (left figure) and wc (right figure) with lvm (n = 206). |
| PubMedID- 25251781 | Background: previous data have suggested the potential risk of low serum-free triiodothyronine (ft3) on the cardiovascular disease (cvd) events in patients with end-stage renal disease (esrd). |
| PubMedID- 24056622 | For the entire cohort of elderly recipients, coronary artery disease and chf were associated with mortality, and in those recipients transplanted after 2000, the risk factors for mortality were coronary artery disease, graft failure, peripheral vascular disease, and cause of end-stage renal disease listed as other. |
| PubMedID- 20124736 | Brachial-ankle pulse wave velocity predicts silent cerebrovascular diseases in patients with end-stage renal diseases. |
| PubMedID- 20400451 | Older patients with end-stage kidney disease often have considerable comorbidity, not only the vascular disease associated with their renal disease, but also the comorbidity found in many older people, including impaired vision, deafness, poor mobility, arthritis and cognitive dysfunction. |
| PubMedID- 26495339 | This discrepancy is attributed to the fact that renal disease can lead to cardiovascular disease (26, 28) and cardiovascular disease, in itself, can result in renal diseases (25, 28). |
| PubMedID- 23420157 | Each patient's medical chart was thoroughly reviewed by nephrologists who extracted data pertaining to the underlying renal disease, history of cardiovascular disease and other comorbid conditions. |
| PubMedID- 20548841 | Serum cystatin c levels in patients with chronic renal disease are associated with cardiovascular disease mortality and all cause mortality [19], and were shown to predict cardiovascular death, myocardial infarction and stroke in a prospective cohort of adults aged ≥ 65 years [12]. |
| PubMedID- 23335472 | In 2006, flores-mateo et al reported that the use of supplements containing selenium did not reduce the risk of coronary heart disease in the meta-analysis of six trials.6 more recently, however, lee et al found that folic acid supplementation with b vitamins had potential small benefits in the prevention of stroke,7 and qin et al indicated that folic acid treatment decreased the risk of cardiovascular disease by 15% in patients with end stage renal disease or advanced chronic kidney disease.8 even though several meta-analyses of randomised controlled trials have been published regarding the efficacy of vitamins and antioxidant supplements on cardiovascular diseases, they involved individual vitamins or antioxidants, and there was no published comprehensive meta-analysis that reviewed this topic all together in one report. |
Page: 1